Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction

NCT07446998 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT07446998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07446998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction
Lead sponsor
Veru Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 26, 2026
Completion date
December 31, 2027
Enrollment
239 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

homa-ir, mobility disability, obesity & overweight